Fundamentals of Therapeutic Antibodies

Mastering biotechnologies and therapeutic innovations

Level 1 -

Fundamentals of Therapeutic Antibodies

Presentation

Why participate?

Understand the key stages of the antibody development cycle. Learn about the tools used to modulate the activity of therapeutic antibodies.

Training Context:

In 2024, 275 therapeutic antibodies are widely used in clinical practice, with the majority being used in oncology, and over 6,000 are currently in development. Among the biopharmaceuticals being developed by biotechnology and pharmaceutical companies, antibodies represent the majority. Since 1986, when the first monoclonal antibody was approved for marketing, knowledge in this field has continued to expand.

Learning objectives

Know the structure of antibodies
Understand the biological functions and mechanisms of action of antibodies
Be familiar with the main approved therapeutic antibodies
Understand the key stages of the antibody development cycle
Learn about tools used to modulate the activity of therapeutic antibodies
Understand the advantages and limitations of therapeutic antibodies

Content

Welcome of participants, introductions

Introduction: Antibodies in the history of medicine: from serotherapy to recombinant antibodies
Physiological functions, structure, and classification of antibodies
Mechanisms of action of antibodies
- Antagonists, neutralizing, agonists, superagonists
- Effector functions of antibodies (antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity)
Clinical successes of antibodies over the past 30 years
- Oncology: solid and hematologic tumors
- Immuno-oncology
- Inflammatory diseases
Key stages of antibody R&D
- Antibody characterization
- Proof of concept in vitro and in vivo
- Pharmacodynamic and pharmacokinetic properties of antibodies
- Bioproduction challenges: scale-up
Modulating antibody activity
- Diversity of antibody formats: Fab’2, scFv, tandem scFv, scFv-Fc, mini-bodies, nanobodies, etc.
- Antibody-drug conjugates
- Bispecific antibodies
What is the role of antibodies in the arsenal of targeted therapies?
- Cell and gene therapy vs. monoclonal antibodies: advantages, limitations, and challenges

General discussion, conclusion, and evaluation

Teaching methods

Interactive Teaching, Case Studies, Experience Sharing

Audience

Business developer, application engineer, research engineer, technician, researcher, manager, from service companies or biotechnology firms

Prerequisites

Have a basic knowledge of biology or have completed the “Fundamentals of Biology and Biotechnology” training

Duration

1 day, 7 hours

Price

750 € HT (Public)

600 € HT (Membre)

300 € HT (Académique)

Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.

Trainers

Catalogue de formations-MabDesign-2023.pdf (3)

Claudine

VERMOT-DESROCHES

Expert consultant in immunotherapies & CEO

TheraWings Consulting

The benefits of our courses

Personalized support
Skills assessment
Certificate of completion
Training quality evaluation
Accessible to people with disabilities (please contact us)

How to access and deadlines

Registering online or by e-mail is a pre-registration. We will process your request within one week:

Contact by e-mail or telephone
Sending of administrative and educational documents: training agreement, training programme and positioning questionnaire.

Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.

When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.

For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr

Level 1 -